Clinical Trial Update: Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating targeted treatment with intercalated radiotherapy in patients with EGFR-mutant IIIA/IIIB non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor | Phase 2, Phase 3 | Status: UNKNOWN